Captrust Financial Advisors Incyte Corp Transaction History

Captrust Financial Advisors

$30.9 Billion
Q2 2024

A detailed history of Captrust Financial Advisors transactions in Incyte Corp stock. As of the latest transaction made, Captrust Financial Advisors holds 7,370 shares of INCY stock, worth $614,510. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,370

Previous 6,549 12.54%

Holding current value

$614,510

Previous $373,000 19.57%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$51.18 - $63.75 $42,018 - $52,338	821 Added 12.54%	7,370 $446,000
Q1 2024 May 15, 2024	SELL	$56.55 - $66.59 $93,646 - $110,273	-1,656 Reduced 20.18%	6,549 $373,000
Q4 2023 Feb 14, 2024	SELL	$52.16 - $64.19 $8,397 - $10,334	-161 Reduced 1.92%	8,205 $515,000
Q3 2023 Nov 14, 2023	BUY	$57.77 - $65.93 $38,590 - $44,041	668 Added 8.68%	8,366 $483,000
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $61,742 - $76,491	1,013 Added 15.15%	7,698 $479,000
Q1 2023 May 15, 2023	SELL	$70.23 - $86.01 $19,804 - $24,254	-282 Reduced 4.05%	6,685 $483,000
Q4 2022 Feb 15, 2023	SELL	$67.18 - $84.11 $82,026 - $102,698	-1,221 Reduced 14.91%	6,967 $559,000
Q3 2022 Nov 16, 2022	BUY	$66.18 - $82.86 $241,292 - $302,107	3,646 Added 80.27%	8,188 $546,000
Q2 2022 Aug 23, 2022	BUY	$66.18 - $83.18 $221,173 - $277,987	3,342 Added 278.5%	4,542 $345,000
Q2 2022 Aug 16, 2022	SELL	$66.18 - $83.18 $143,081 - $179,835	-2,162 Reduced 64.31%	1,200 $91,000
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $95,134 - $114,862	1,441 Added 75.01%	3,362 $267,000
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $79,111 - $92,563	1,249 Added 185.86%	1,921 $141,000
Q3 2021 Nov 16, 2021	BUY	$68.67 - $84.02 $10,437 - $12,771	152 Added 29.23%	672 $46,000
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $8,705 - $9,540	109 Added 26.52%	520 $44,000
Q1 2021 May 17, 2021	SELL	$76.02 - $100.5 $42,419 - $56,079	-558 Reduced 57.59%	411 $33,000
Q4 2020 Feb 16, 2021	SELL	$80.74 - $97.7 $88,006 - $106,493	-1,090 Reduced 52.94%	969 $84,000
Q3 2020 Nov 17, 2020	BUY	$85.07 - $109.69 $116,716 - $150,494	1,372 Added 199.71%	2,059 $190,000
Q2 2020 Aug 14, 2020	SELL	$74.18 - $108.93 $251,396 - $369,163	-3,389 Reduced 83.15%	687 $71,000
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $177,156 - $241,059	-2,804 Reduced 40.76%	4,076 $302,000
Q4 2019 Feb 14, 2020	BUY	$73.04 - $95.72 $473,299 - $620,265	6,480 Added 1620.0%	6,880 $591,000
Q3 2019 Nov 14, 2019	SELL	$72.82 - $86.52 $1,019 - $1,211	-14 Reduced 3.38%	400 $30,000
Q2 2019 Aug 13, 2019	BUY	$73.52 - $88.7 $30,437 - $36,721	414 New	414 $35,000
Q3 2018 Nov 15, 2018	SELL	$61.75 - $74.23 $123 - $148	-2 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$60.85 - $83.98 $121 - $167	2 New	2 $0

Others Institutions Holding INCY

# of Institutions

629

Shares Held

198M

Call Options Held

763K

Put Options Held

476K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $18.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.

Account

Captrust Financial Advisors Incyte Corp Transaction History